BioBlast Pharma Ltd, a clinical stage biotechnology company focusing on therapies for rare genetic diseases, is celebrating its recent IPO and the end of its quiet period with a visit to the NASDAQ MarketSite in Times Square. CEO Dr. Dalia ...

Teva Pharmaceutical Industries Ltd. is issuing a Class II recall of one lot (3,881 bottles) of carbidopa/levodopa 25 mg/100 mg, a generic drug used to treat Parkinson’s disease, due to the potential for “superpotent” tablets. The lot in question was manufactured ...

Macrocure Ltd., a clinical-stage biotech company developing treatments for chronic and hard-to-heal wounds, recently announced second quarter financial results. Highlights noted in the fiscal summary include: In June, a meeting with the Data Safety Monitoring Board (DSMB) resulted in an advisement ...

With the recent U.S. Food and Drug Administration approval of Sanofi SA’s drug Cerdelga to treat patients with Type I Gaucher’s disease, the share price of Protalix Biotherapeutics Inc. plummeted to its lowest point in five years. Cerdelga (eliglustat) was developed by ...

Foreign press is calling it “the most embarrassing IPO fiasco of the decade.” The initial public offering of VBL Therapeutics was terminated by the company’s underwriters, Deutsche Bank and Wells Fargo, after trading for only four days. US venture capital fund ...

Foamix Pharmaceuticals, an Israeli biotech developing topical foam treatments for various skin diseases, filed a draft prospectus on Wednesday with the SEC to raise up to $75 million in an initial public offering. The company expects to enter Phase III ...